Drug Trial Radar · NCT04393038
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
509
Actual
Start
Jul 1, 2020
Primary completion
Mar 5, 2021
Study completion Apr 16, 2021
Sponsor
- Lead sponsor
- Abivax S.A.Industry
- Sponsor type
- Industry
- First posted
- May 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing acute respiratory failure in patients aged ≥65 and patients aged ≥18 with at least one additional risk factor who are infected with SARS-CoV-2 (the MiR-AGE study).
Conditions
- COVID-19
Interventions
ABX464Drug
ABX464 50mg QD for 28 days + Standard of Care
PlaceboDrug
Placebo 50mg QD for 28 days + Standard of Care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Responders: i.e. Rate of Patients Who do Not Require Use of High-flow Oxygen Invasive or Non-invasive Mechanical Ventilation (IMV and NIV, Respectively) Within 28 Days and Who Are Alive at the End of the 28 Days Period.Time frame: 28 days
Locations
30 sites in 8 countries. Site status is shown where the registry gives one.
Centre hospitalier Saint Pierre
Brussels, Belgium
Hôpital Erasme
Brussels, Belgium
UZ Gent
Ghent, Belgium
Instituto Nacional de Infectologia Evandro Chagas - FIOCRUZ Rio de Janeiro
Rio de Janeiro, Brazil
Conjunto Hospitalar do Mandaqui
São Paulo, Brazil
Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado - Instituto de Pesquisa Clínica Carlos Borborema
Manaus, Amazonas, Brazil
Centro Oncológico de Roraima - CECOR - NAP
Boa Vista, Roraima, Brazil
Hospital das Clinicas da FMUSP
São Paulo, São Paulo, Brazil
Hôpital Nord
Amiens, France
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon, France
Centre Hospitalier Universitaire de Nice
Nice, France
Hôpital Saint-Antoine
Paris, France
Asklepios Klinik St. Georg
Hamburg, Germany
Asklepios Klinik Altona
Hamburg, Germany
Universitätsmedizin Mannheim Ruprecht-Karls-Universität Heid
Mannheim, Baden-Wurttemberg, Germany
Universitätsklinikum Bonn
Bonn, North Rhine-Westphalia, Germany
Ospedale A. Manzonidi Lecco - ASST Lecco
Lecco, Italy
Ospedale Niguarda
Milan, Italy
Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico - Infectious Diseases
Milan, Lombardy, Italy
Ospedale San Paolo
Milan, Lombardy, Italy
Ospedale Luigi Sacco, AO-PU
Milan, Lombardy, Italy
Ospedale di Vittorio Veneto - Medecina generale
Vittorio Veneto, Treviso, Italy
Centro de Prevención y Rehabilitación de Enfermedades Pulmon
Nuevo León, Mexico
Consultorio médico
Mérida, Yucatán, Mexico
H.G.U. Alicante
Alicante, Spain
Hospital del Mar
Barcelona, Spain
Hospital de La Princesa
Madrid, Spain
Hospital Universitario Infanta Leonor
Madrid, Spain
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain
Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.